journal article·2019-12-04Open access

RETRACTED ARTICLE: GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response

Qini Zhao, Haiming Xu, Lirong Zhang, Long Liu, Libo Wang

This record is marked as retracted by the source. Review the publisher’s notice before using its findings.

Abstract

Increased free fatty acids (FFA) are one of the risk factors for type 2 diabetes. FFA also contribute to endothelial dysfunction in both the prediabetes and diabetes conditions. Therefore, FFA are an important link between diabetes and endothelial dysfunction. In therapeutic application, GLP-1 receptor agonists have been implemented to lower blood glucose in diabetes. Here, we investigate the role of the common clinically used GLP-1 receptor agonist lixisenatide in endothelial cells. We demonstrate that lixisenatide could protect endothelial cells from high FFA-induced toxicity and cell death. Lixisenatide also suppresses FFA-caused cellular ROS generation and production of the lipid oxidation byproduct 4-HNE. Lixisenatide inhibits FFA-triggered production of TNF-α, IL-6, VCAM-1 and ICAM-1. The presence of lixisenatide in co-culture experiments suppresses adhesion of monocytes to endothelial cells. Moreover, lixisenatide ameliorates FFA-induced decreased eNOS phosphorylation and NO reduction. We also demonstrate that lixisenatide inhibits FFA-induced IκBα activation, nuclear p65 translocation and NF-κB activation. This evidence indicates that lixisenatide suppresses activation of the NF-κB pathway in endothelial cells. Collectively, our findings suggest that lixisenatide might have therapeutic potential to modulate diabetes-associated vascular complications.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Diet and metabolism studies · Pharmacology and Obesity Treatment · Regulation of Appetite and Obesity

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Cardiovascular Medicine, China-Japan Union Hospital of Jilin University

Jilin Provincial Precision Medicine Key Laboratory for Cardiovascular Genetic Diagnosis

Department of Pathology, China-Japan Union Hospital of Jilin University

Department of Neurology, China-Japan Union Hospital of Jilin University

References

Reference metadata was not supplied for this record.